Physician profile
Danielle N Brown
NPI 1346864881
$2,032.97
in general payments reported to CMS, 2019-2025
13 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $1,135 · 2024: $469 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.87 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.07 | 2023-2024 | |
| Glaxosmithkline, LLC. | $312.22 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $289.94 | 2023-2024 | Dupixent |
| Medtronic, INC. | $246.69 | 2022-2023 | Nuvent |
| Pharming Healthcare, INC. | $148.43 | 2023-2024 | Joenja, Ruconest |
| Genzyme Corporation | $137.10 | 2023-2025 | |
| Optinose US, INC. | $122.38 | 2025 | |
| Alkermes, INC. | $88.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $51.11 | 2024 | |
| Acclarent, INC | $48.94 | 2023-2024 | Acclarent Aera, Trudi Nav Cable |
| Alk-Abello, INC | $34.88 | 2023-2024 | Grastek, Ragwitek, Odactra |
| Merck Sharp & Dohme LLC | $26.39 | 2023 | |
| Galderma Laboratories, L.P. | $16.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.